Company Encyclopedia
View More
name
HESH
301103.SZ
Liaoning He Eye Hospital Group Co., LTD. provides ophthalmic specialist diagnosis, treatment, and optometry services to patients with eye diseases. It offers cataract diagnosis and treatment, refractive error surgical correction, vitreoretinal diagnosis and treatment, other surgical diagnosis and treatment services, etc. The company also provides refractive cataracts, LASIK surgery, myopia prevention, medical fitting, diabetic retinopathy, dry eyes and cornea, gene diagnosis, and comprehensive eye disease solutions.
83.64 B
301103.SZMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
Health Care ServicesIndustry
Industry Ranking5/8
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.55%D
    • Profit Margin0.98%C
    • Gross Margin41.56%B
  • Growth ScoreC
    • Revenue YoY-1.80%D
    • Net Profit YoY154.52%A
    • Total Assets YoY-2.09%D
    • Net Assets YoY-0.80%D
  • Cash ScoreB
    • Cash Flow Margin10224.45%A
    • OCF YoY-1.80%D
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreA
    • Gearing Ratio15.26%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HESH released its performance for the first three quarters, with a net profit attributable to the parent company of 54.3953 million yuan, an increase of 232.18%

    HESH released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 855 million yuan, a year-on-year decrease of 1.11%. The net profit attributable to the parent company was 54.3953 million yuan, a year-on-year increase of 232.18%; the net profit excluding non-recurring gains and losses was 42.4287 million yuan, a year-on-year increase of 186.89%. The basic earnings per share were 0.3442 yuan

    Zhitong·
    SZ
    301103
    -0.71%
    Zhitong·
    SZ
    301103
    -0.71%

    HESH plans to grant 6.37 million shares of restricted stock

    HESH announced the 2025 restricted stock incentive plan, intending to grant 6.37 million shares of restricted stock, of which 5.1 million shares will be granted for the first time. The number of incentive recipients will not exceed 240, with a grant price of 13 yuan per share and a maximum validity period of 60 months

    Zhitong·
    SZ
    301103
    -0.71%
    Zhitong·
    SZ
    301103
    -0.71%

    Ophthalmology medical concept stocks surged, SPAS hit the daily limit in the afternoon

    Ophthalmology medical concept stocks surged during the session, with SPAS hitting the daily limit, Xingqi Eye Medicine rising over 10%, Lifeon Pharmaceutical previously hitting the daily limit, and Bio-S, Eyebright Medical, GZYK, and HESH also following suit

    Zhitong·
    SZ
    003020
    +0.30%
    SZ
    301096
    +3.79%
    SH
    688050
    -0.55%
    Zhitong·
    SZ
    003020
    +0.30%
    SZ
    301096
    +3.79%
    SH
    688050
    -0.55%

    HESH: In the first half of 2025, the net profit was 44.3246 million yuan, a year-on-year increase of 84.19%

    HESH announced that in the first half of 2025, operating revenue was 560 million yuan, a year-on-year decrease of 4.22%. Net profit was 44.3246 million yuan, a year-on-year increase of 84.19%

    Zhitong·
    SZ
    301103
    -0.71%
    Zhitong·
    SZ
    301103
    -0.71%

    HESH: The company has not signed any agency or cooperation agreements with any artificial cornea companies in Japan

    HESH responded on the interactive platform on August 12, stating that as of now, the company has not signed any agency or cooperation agreements with any artificial cornea companies in Japan. The company has been closely monitoring the advancements in advanced ophthalmic technologies and products globally, including but not limited to the latest developments in artificial cornea research in Japan, the United States, and Europe

    Zhitong·
    SZ
    301103
    -0.71%
    Zhitong·
    SZ
    301103
    -0.71%
    © 2025 Longbridge｜Disclaimer